Seattle is home to a sophisticated biotechnology and immunotherapy research community where antibody discovery often depends on more than identifying molecules that bind a target. Researchers may need antibodies that neutralize a ligand, recognize a native cell surface receptor, trigger or block a biological response, internalize efficiently, or perform reliably in a defined experimental system.
At Precision Antibody, we develop custom monoclonal antibodies around the biological application that matters to the research program. Our services support Seattle biotechnology companies, academic researchers, translational science teams, therapeutic discovery groups, and other organizations that need custom antibody development, fully human monoclonal antibody development, functional assay services, internalization assays, and related antibody characterization.
Our antibody development work is performed at our Columbia, Maryland facility. We serve research organizations in Seattle and other biotechnology markets without representing that we operate a laboratory or office in Washington. For Seattle research teams, the value is access to specialized antibody development capabilities, scientific consultation, functional screening, and project support that can be aligned with the intended use of the antibody.
Precision Antibody was founded by scientists, run by scientists, and created for scientists. We are experts in antibody development, but what makes us different from all the other antibody development experts out there?
Precision Antibody’s founder Dr. Jun Hayashi is an accomplished Developmental Immunologist who has established the antibody development platform unique to the company. Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy.
Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy. They have been working together and have had long and successful careers in Academia and Industry.
They lead Precision Antibody with a core team of Ph.Ds. with expertise in Immunology, Cancer Biology, Biochemistry, Molecular & Cell Biology, and Developmental Biology. Our team’s wide range of skills and knowledge allows us to understand your goal in the global biology context and enable us to provide professional guidance in designing and implementing a perfect project to successfully develop antibodies that will meet customer’s expectations.
A successful custom antibody program begins with a clear understanding of what the antibody ultimately needs to do.
Some projects require strong and selective binding. Others require recognition of a native protein conformation, activity against a receptor, performance in flow cytometry, biological neutralization, receptor internalization, or compatibility with a downstream therapeutic or analytical workflow.
At Precision Antibody, we approach custom antibody development with the intended application in mind. This distinction is important because an antibody that binds purified antigen well may not necessarily perform equally well in a cellular, functional, or translational setting.
For Seattle researchers evaluating custom antibody development services, our approach can support projects involving therapeutic discovery, immunotherapy research, target validation, receptor biology, antibody drug conjugate programs, biomarker research, and other applications where antibody performance needs to be measured in a meaningful biological context.
The intended application can influence multiple stages of an antibody program, including antigen strategy, immunization, screening, clone prioritization, and characterization.
Rather than treating antigen recognition as the only endpoint, we can incorporate application relevant screening criteria into the development process when the project requires them. This helps create a more informative path from antibody generation to candidate selection.
A research team developing antibodies against a cell surface receptor, for example, may need to know whether promising clones bind cells expressing the native target. If the project involves receptor internalization, then cellular uptake may become a meaningful selection criterion. If the objective involves neutralization, candidates may need to be compared based on functional activity rather than binding strength alone.
This application focused approach is central to how we think about antibody development.
Although every custom antibody program is different, the overall development process can involve several connected stages.
Scientific consultation and project definition
Antigen and immunization strategy
Antibody generation
Screening against relevant targets or assay conditions
Clone selection
Functional testing when required
Characterization of promising candidates
Delivery of project materials and data according to the agreed project scope
The details of each stage depend on the biological target, required antibody characteristics, intended application, timeline, and downstream research needs.
Antigen selection can have a substantial effect on the antibody populations generated during a project.
The appropriate strategy depends on the biology of the target and how the final antibody will be used. A purified protein, peptide, recombinant domain, cell associated antigen, or other target presentation may create different screening and development considerations.
Our project discussions are intended to identify these considerations before the development process advances. When the final application depends on native conformation, cellular recognition, functional activity, or another specialized characteristic, those requirements should influence the development strategy from the beginning.
Screening is where antibody development becomes closely connected to practical research needs.
Binding assays can help identify target reactive candidates, but additional screening may be necessary when the antibody must perform a specific biological function.
Depending on the program, screening can incorporate considerations such as:
Binding to the desired target
Recognition of a native or cell associated protein
Relative affinity or binding behavior
Functional activity
Receptor internalization
Neutralization
Flow based performance
Other project specific biological criteria
The goal is not to add testing unnecessarily. It is to generate information that helps researchers distinguish between candidates in a scientifically meaningful way.
Fully human monoclonal antibodies can be valuable for therapeutic discovery programs seeking human antibody candidates directly from the antibody generation process.
Precision Antibody offers fully human monoclonal antibody development using Trans Chromosomics mouse technology. These mice are designed to generate fully human IgG antibodies following immunization, providing a route to fully human antibody candidates without making a separate humanization step an automatic requirement for every selected clone.
For Seattle immunotherapy and therapeutic research teams, this capability can support programs where fully human antibody discovery, functional screening, and candidate characterization need to be integrated into a focused development process.
Fully human antibody development begins with the same fundamental question as other antibody programs: what does the research team need the antibody to recognize and accomplish?
The presence of fully human antibody sequences does not remove the need for careful antigen strategy, screening, functional assessment, or characterization. A therapeutic research program still needs to identify candidates that meet the biological requirements of the target and the intended application.
Our fully human monoclonal antibody program is designed to combine the advantages of immunization based antibody discovery with the ability to generate fully human IgG candidates.
This can be relevant for projects involving:
Therapeutic target discovery
Immuno oncology research
Receptor targeted antibody programs
Antibody drug conjugate research
Neutralizing antibody development
Cell surface target programs
Other applications where fully human monoclonal antibodies are preferred
Fully human antibodies may be especially relevant when the downstream program is expected to move toward therapeutic evaluation.
One potential advantage is the ability to begin with fully human antibody candidates rather than generating a nonhuman monoclonal antibody and assuming a later humanization step will be required.
The appropriate discovery strategy still depends on the target, biological mechanism, required diversity, screening method, development goals, and other project specific factors. A fully human platform should therefore be evaluated as part of the overall discovery plan rather than as an isolated technology choice.
For Seattle researchers working in immunotherapy, protein therapeutics, oncology, or translational biology, this approach can help connect antibody generation with downstream candidate evaluation earlier in the discovery process.
Precision Antibody positions its fully human monoclonal antibody development program around an approximately 60 day development timeline.
That timeframe applies specifically to the fully human program and should not be interpreted as a universal turnaround for every custom antibody project. Project schedules vary according to target complexity, screening requirements, functional testing, characterization, and other scientific factors.
Speed is useful when it helps a research team reach meaningful decisions sooner. It is less useful if rapid generation produces a large set of candidates without enough information to understand which antibodies are most suitable for the intended application.
Our objective is therefore to combine timely development with scientifically relevant screening and characterization.
Functional assays help answer a question that binding data alone cannot always resolve:
Does the antibody produce the biological effect required by the research program?
This question becomes increasingly important as antibody programs move from antigen recognition toward therapeutic discovery, receptor biology, immunotherapy, or other functional applications.
Precision Antibody supports custom functional assay services that can be incorporated into antibody development or used to evaluate selected candidates.
Neutralization assays can help determine whether an antibody interferes with a ligand, receptor interaction, signaling event, or other biological process relevant to the target.
Depending on the project, functional evaluation may involve ligand neutralization, receptor neutralization, agonistic activity, inhibition, or another measurable biological response.
The assay design must match the mechanism being investigated.
A useful functional assay should therefore begin with clearly defined biological questions. Those questions can include:
What molecular interaction should the antibody influence?
What cellular or biochemical response should change?
Which experimental model best represents the intended mechanism?
What readout will allow meaningful candidate comparison?
What controls are required to interpret the result?
By defining these factors early, functional testing can become a decision tool rather than simply another data point.
Flow cytometry can be particularly useful for antibody programs involving cell surface targets.
Cell based screening may help determine whether antibodies recognize the native target as it appears on relevant cells, rather than relying solely on binding to purified material.
Depending on the project, flow based assays can support evaluation of:
Cell surface binding
Target dependent recognition
Relative staining behavior
Receptor occupancy
Internalization
Functional effects that can be detected through cellular markers
This type of screening can be valuable when the target conformation or cellular environment is important to antibody performance.
The antibody with the strongest apparent binding signal is not always the antibody with the most useful biological activity.
Two antibodies directed against the same target can behave differently because they recognize different epitopes, interact with the target at different angles, exhibit different binding kinetics, or influence receptor function differently.
For this reason, functional screening can change which candidates a research team chooses to advance.
A candidate with excellent affinity but weak internalization may be less attractive for certain antibody drug conjugate programs than a candidate with somewhat different binding properties but stronger receptor mediated uptake. Similarly, an antibody that binds a receptor strongly may not be the best choice if it does not generate the required neutralizing or agonistic response.
Functional data therefore help place binding results in biological context.
Antibody internalization assays measure whether an antibody bound to a cell surface target is taken into the cell after receptor engagement.
This process is especially relevant to research programs where cellular uptake is part of the desired mechanism, including many antibody drug conjugate and receptor targeted therapeutic strategies.
Seattle has a strong history of research and innovation related to targeted oncology and antibody drug conjugate development. For research teams working in this area, internalization can be an important characteristic when comparing antibody candidates.
An internalization assay evaluates the movement of a target bound antibody from the cell surface into the cell.
The exact assay format depends on the target, cell model, antibody, detection method, incubation conditions, and research objective. The result can help researchers determine whether target engagement leads to cellular uptake and whether different antibody candidates show meaningful differences in internalization behavior.
This information can be useful when the biological mechanism requires the antibody, receptor complex, or attached payload to move into the cell.
Antibody drug conjugates rely on multiple biological properties working together.
Target expression, specificity, accessibility, antibody binding, receptor behavior, internalization, intracellular trafficking, linker characteristics, and payload biology can all influence how an ADC behaves.
Internalization assays address one part of that broader problem by helping researchers determine whether an antibody candidate is taken into target expressing cells after binding.
An antibody may demonstrate strong surface binding while showing limited uptake. Another antibody against the same target may internalize more efficiently.
When internalization is important to the intended mechanism, this difference can affect candidate prioritization.
Internalization can be evaluated after promising antibodies have been identified, or it can be incorporated more directly into candidate screening when uptake is a major program objective.
The appropriate approach depends on the size of the antibody panel, available cell models, target biology, and the stage of discovery.
A practical internalization screening strategy may consider:
Target expression on the selected cells
Specificity of antibody binding
Internalization kinetics
Relative uptake among antibody candidates
Controls for surface associated versus internalized signal
Assay reproducibility
Compatibility with downstream functional requirements
Strong target binding confirms that an antibody recognizes the intended molecule. It does not automatically establish what happens after that interaction.
For receptor targeted programs, downstream behavior may matter as much as initial binding.
Questions may include whether the antibody remains on the cell surface, whether the receptor antibody complex is internalized, how quickly uptake occurs, and whether the biological response aligns with the project objective.
This is why binding and internalization should be considered related but distinct characteristics.
Once promising antibody candidates have been identified, characterization can help researchers compare them more precisely.
Characterization may include binding analysis, affinity measurement, binding kinetics, specificity assessment, epitope relationships, functional performance, and other project appropriate measurements.
The purpose is not simply to produce additional data. The purpose is to generate evidence that supports candidate decisions.
Affinity describes the strength of the overall antibody antigen interaction. Binding kinetics provide additional information about how quickly the antibody associates with and dissociates from the target.
These measurements can help distinguish between antibodies that appear similar in a basic binding assay.
A slower off rate, for example, may be useful in some applications, while another project may place greater importance on epitope, functional response, internalization, or cellular specificity.
Binding characteristics should therefore be interpreted in the context of the intended application.
Precision Antibody supports antibody characterization using technologies that include Octet and Biacore.
These approaches can provide quantitative information about antibody target interactions and help researchers compare candidate binding behavior.
The most useful characterization strategy depends on what the research team needs to learn. A program focused on therapeutic lead selection may require different information from a program focused on assay reagent development.
Lead selection becomes more informative when biological activity and biophysical data can be considered together.
A research team may compare candidates based on:
Target specificity
Binding strength
Association and dissociation behavior
Cellular recognition
Neutralization
Internalization
Other functional characteristics
The best candidate is not always the antibody with the highest value in a single measurement. It is the candidate that best fits the biological and development requirements of the program.
Seattle has developed a strong reputation in immunotherapy, oncology, protein science, translational research, and biotechnology.
That research environment creates demand for specialized tools and external development capabilities that can support complex biological programs without requiring every organization to build each technology platform internally.
Precision Antibody serves Seattle research teams by providing custom antibody development, fully human monoclonal antibody generation, functional screening, internalization assays, and related characterization from our Maryland laboratory.
Antibodies can play several roles in immunotherapy research.
Depending on the biological mechanism, researchers may investigate antibodies that block inhibitory interactions, activate receptors, neutralize soluble factors, recognize disease associated cell surface targets, deliver therapeutic payloads, or support other immune based approaches.
Each application introduces different antibody selection criteria.
An antibody intended to neutralize a ligand may require a different screening strategy from an antibody intended to internalize after binding a tumor associated receptor. The ability to align the development process with those biological requirements can make candidate evaluation more relevant.
Seattle’s history in antibody drug conjugate research makes internalization and receptor targeted antibody development particularly relevant to the local biotechnology community.
For an ADC oriented research program, antibody development may involve several layers of candidate assessment:
Target recognition
Cell surface binding
Specificity
Internalization
Binding kinetics
Functional behavior
Compatibility with later conjugate development requirements
Not every antibody development project requires all of these measurements, but researchers benefit from being able to select the assays that address their most important program risks.
Seattle also supports a broad ecosystem of protein engineering, therapeutic discovery, and translational biology.
For these research teams, custom antibodies can serve as therapeutic candidates, biological probes, analytical reagents, assay components, target validation tools, or development reagents.
The antibody development strategy should reflect the intended role.
A research reagent may be selected primarily for specificity and assay performance. A therapeutic discovery candidate may require deeper functional and biophysical assessment. A bioanalytical program may need antibodies optimized for detection of a particular molecule in a defined assay format.
A custom antibody project is most useful when the scientific objective is clear from the beginning.
Our process is designed around communication, defined project phases, and development milestones so researchers can understand how the program is progressing.
The first step is to discuss the target and intended application.
Important questions may include:
What is the biological target?
What antibody format is required?
How will the antibody ultimately be used?
Is native cellular recognition important?
Is functional activity required?
Does the antibody need to internalize?
Will affinity or kinetic characterization be needed?
Are there specific timeline or material requirements?
These questions help establish a development strategy that matches the research objective.
After project design, antibody generation proceeds according to the selected platform and immunization strategy.
Screening can then identify candidates that meet the agreed selection criteria.
Depending on the program, this may begin with target binding and progress into more specialized screening.
A therapeutic research program, for example, may move from initial candidate identification into cellular binding, neutralization, internalization, or biophysical characterization.
Functional testing can be introduced when biological activity is a meaningful part of candidate selection.
Characterization can provide additional information regarding candidate binding properties and behavior.
Together, these data can help research teams move from a broad pool of target reactive antibodies toward a smaller group of candidates that better match the project objective.
Precision Antibody structures projects around defined phases and milestones.
This approach allows researchers to review progress and data as the program advances.
We also state that customers own the antibody clones developed through their custom projects. For biotechnology and therapeutic discovery organizations, ownership can be an important consideration when choosing an external antibody development partner.
Our development work is performed at our Columbia, Maryland facility, and projects are managed with confidentiality and scientific communication in mind.
Antibody discovery frequently creates needs beyond the initial generation of monoclonal antibodies.
Depending on the research program, additional support may involve production, purification, characterization, sequencing, functional evaluation, assay development, or antibodies created for bioanalytical applications.
Therapeutic antibody programs may eventually require reagents that recognize the therapeutic antibody itself.
Precision Antibody has completed more than 200 anti idiotype projects and provides custom anti idiotype antibody development for applications that can include pharmacokinetic and other bioanalytical assay needs.
These projects can require careful selection of antibody pairs, affinity characteristics, off rate behavior, and performance in relevant matrices.
Anti idiotype development is distinct from the fully human therapeutic antibody discovery work discussed throughout this page, but it can become an important supporting capability as antibody programs advance.
Selected monoclonal antibodies may require additional production and purification for downstream research.
Characterization can also help researchers better understand selected clones before committing resources to later stages of a program.
The exact scope should be defined according to the amount of material required, antibody format, experimental use, and the level of characterization necessary for the next research decision.
Precision Antibody positions its fully human monoclonal antibody development program around an approximately 60 day timeline.
Actual project requirements can vary, particularly when specialized functional screening, additional characterization, or target specific considerations are involved. The approximately 60 day timeline should therefore be understood as a program specific development timeframe rather than a guarantee that every antibody project follows the same schedule.
Binding screening determines whether an antibody recognizes the intended target. Functional screening evaluates whether the antibody produces or influences a biological effect relevant to the research objective.
An antibody may bind strongly without neutralizing a ligand, triggering a receptor response, or internalizing efficiently.
For projects where biological activity matters, both types of information can contribute to candidate selection.
Internalization assays help determine whether a target bound antibody is taken into the cell after receptor engagement.
This characteristic can be important for antibody drug conjugate research because many ADC strategies depend on cellular uptake as part of the mechanism used to deliver a payload.
Internalization is only one component of ADC development, but it can provide valuable information when researchers compare antibodies directed against the same target.
Yes. Precision Antibody can incorporate functional screening and biological assays into custom antibody development when the project requires them.
The appropriate assay depends on the target and intended mechanism. Examples can include ligand neutralization, receptor neutralization, internalization, flow based screening, and other custom biological assays.
The most effective approach is to define the required functional characteristic during project planning so the development and screening strategy can reflect that goal.
No. Affinity is important, but it is only one characteristic of an antibody.
The most appropriate candidate may depend on epitope, specificity, binding kinetics, cellular recognition, internalization, neutralization, agonistic activity, or another functional property.
Lead selection is strongest when the measurements used to compare antibodies are aligned with the biological role the antibody is expected to perform.
Fully human antibody discovery can provide antibody candidates with fully human IgG sequences directly from the discovery platform, which can remove the assumption that a separate humanization step will always be needed.
Whether additional sequence engineering or development work is appropriate depends on the individual candidate and downstream program requirements.
Precision Antibody states that customers own the antibody clones developed through their custom development projects.
This can be an important consideration for biotechnology companies, academic research programs, and therapeutic discovery teams that want clarity around ownership of materials generated during outsourced antibody development.
Precision Antibody performs antibody development work at its facility in Columbia, Maryland.
We support researchers and biotechnology organizations in Seattle and other markets from that facility. We do not represent that we maintain a Precision Antibody laboratory or office in Seattle.
A productive initial discussion usually includes the biological target, intended application, desired antibody format, known target characteristics, preferred screening approach, functional requirements, expected material needs, and project timeline.
If the antibody is intended for a specialized use such as receptor internalization, neutralization, or therapeutic discovery, sharing that objective early can help shape the development strategy.
Seattle researchers working in immunotherapy, oncology, protein therapeutics, antibody drug conjugates, receptor biology, and translational science often need antibody programs that connect discovery with biological relevance.
At Precision Antibody, we focus on that connection.
Our custom antibody development services can support target specific monoclonal antibody generation, fully human antibody discovery, functional assays, receptor internalization studies, flow based screening, binding characterization, and other project specific requirements.
The objective is not simply to generate antibodies. It is to help research teams identify antibodies that are better aligned with the scientific question they are trying to answer.
For Seattle biotechnology companies, academic groups, and therapeutic research teams evaluating an antibody development project, the most useful starting point is a clear discussion of the target, intended application, functional requirements, and candidate selection criteria. From there, we can define an antibody development and screening strategy that reflects the biology of the program and the decisions the research team needs to make.
Precision Antibody™ is the forefront of the global Custom Antibody industry & it is led by the innovative minds in immunology and antibody development field.
